CellBioMedGroup Profile Banner
Cellular Biomedicine Group, Inc Profile
Cellular Biomedicine Group, Inc

@CellBioMedGroup

Followers
211
Following
15
Media
9
Statuses
148

CBMG develops proprietary cell therapies for the treatment of cancerous and autoimmune diseases.

USA
Joined November 2012
Don't wanna be here? Send us removal request.
@CAR_TCell
CAR-TCR
2 years
Nektar Therapeutics Announces New Clinical Study Collaboration with Cellular Biomedicine Group Inc. to Evaluate NKTR-255 in Combination with C-TIL051 in Advanced Non-Small Cell Lung Cancer: https://t.co/bMNujqGBJw #CARTCR
0
1
1
@JNJInnovMed
J&J Innovative Medicine
3 years
Janssen announced a worldwide collaboration and license agreement with @CellBioMedGroup to develop next generation CAR-T therapies for the treatment of patients with B-cell malignancies: https://t.co/DiX6PPaHbR #BloodCancer
0
1
8
@CellBioMedGroup
Cellular Biomedicine Group, Inc
3 years
Expanding the potential of promising NHL drug candidates; CBMG announces exclusive collaboration & license agreement with @JanssenGlobal for anti CD19 & CD20 Bi-Specific and anti CD20 CAR-Ts for Non-Hodgkin Lymphoma #nonHodgkin #lymphoma #immunotherapy
Tweet card summary image
prnewswire.com
/PRNewswire/ -- Cellular Biomedicine Group Inc. (CBMG or the Company), a clinical-stage biopharmaceutical company focused on discovery and development of...
0
1
3
@CellBioMedGroup
Cellular Biomedicine Group, Inc
3 years
CBMG granted FDA Clearance of IND Application for Novel TIL Therapy C-TIL051 for treatment of NSCLC
prnewswire.com
/PRNewswire/ -- Cellular Biomedicine Group Inc. (CBMG or the "Company"), a biopharmaceutical company developing innovative cellular immunotherapies for the...
0
0
0
@CellBioMedGroup
Cellular Biomedicine Group, Inc
4 years
CBMG Receives FDA RMAT and Fast Track Designations for Bi-Specific Anti-CD19/CD20 CAR-T Cell Therapy for Relapsed/Refractory B-cell Non-Hodgkin Lymphoma https://t.co/7FCfPvsKJa
0
0
0
@CellBioMedGroup
Cellular Biomedicine Group, Inc
4 years
CBMG Receives FDA Clearance of IND Application for CAR-T Cell Therapy for non-Hodgkin Lymphoma
Tweet card summary image
prnewswire.com
/PRNewswire/ -- Cellular Biomedicine Group Inc. (CBMG or the "Company"), a biopharmaceutical company developing innovative cellular immunotherapies for the...
0
0
0
@CellBioMedGroup
Cellular Biomedicine Group, Inc
5 years
CBMG Announces Data from Two CAR-T Clinical Studies Selected for Podium Presentations at ASCO Annual Meeting #asco #cbmg
0
0
0
@CellBioMedGroup
Cellular Biomedicine Group, Inc
5 years
CBMG Announces Completion of Merger, common stock no longer trading on Nasdaq
0
0
0
@CellBioMedGroup
Cellular Biomedicine Group, Inc
5 years
CBMG Stockholders Approve Merger
0
0
0
@CellBioMedGroup
Cellular Biomedicine Group, Inc
5 years
Proxy Advisory Firms Glass Lewis & ISS Recommend $CBMG Stockholders Vote FOR Proposed Merger
0
0
0
@CellBioMedGroup
Cellular Biomedicine Group, Inc
5 years
$CBMG CAR T-Cell Therapy Data to be Presented at 2020 ASH Annual Meeting
0
0
0
@CellBioMedGroup
Cellular Biomedicine Group, Inc
5 years
CBMG Reports Q3 2020 Financial Results and Business Highlights
0
0
0
@CellBioMedGroup
Cellular Biomedicine Group, Inc
5 years
$CBMG Q2 2020 financial & business highlights
0
0
0
@CellBioMedGroup
Cellular Biomedicine Group, Inc
5 years
$CBMG in Definitive Merger Agreement, would result in Company going private
0
0
0
@CellBioMedGroup
Cellular Biomedicine Group, Inc
6 years
$CBMG R&D Showcase presentation today
0
0
0
@CellBioMedGroup
Cellular Biomedicine Group, Inc
6 years
Results from $CBMG annual stockholder meeting
0
0
0
@CellBioMedGroup
Cellular Biomedicine Group, Inc
6 years
$CBMG poster on TCRs targeting AFP-Positive Liver Cancer at @AACR Annual Meeting today
0
0
0
@CellBioMedGroup
Cellular Biomedicine Group, Inc
6 years
Notice of $CBMG 2020 Annual Meeting of Stockholders
0
0
0
@CellBioMedGroup
Cellular Biomedicine Group, Inc
6 years
$CBMG Q1 2020 report
0
0
0
@CellBioMedGroup
Cellular Biomedicine Group, Inc
6 years
CBMG Q1 earnings call scheduled for May 6
0
0
0